← Leaderboards
Joseph F Quinn
Oregon Health And Science University
$13,031,665
Attributed
$14,811,480
Total exposure
20
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,811,480 · 16
VA$0 · 4
By mechanism
U01$6,119,315 · 1
P30$2,123,445 · 5
U10$1,557,196 · 1
P50$1,377,129 · 2
UH3$1,222,405 · 1
UH2$793,119 · 1
Top collaborators
- Julie Anne Saugstad7 shared
- Amala Soumyanath3 shared
- Philip F Copenhaver1 shared
- Martin Jeffrey Kelly1 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Svetlana Lutsenko$18,670,781
- Charles E Roselli$10,845,749
- Doris Kretzschmar$7,049,005
- Jack H Kaplan$8,104,976
- Michael R Powers$1,895,628
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePlasmaClinical TrialsDementiaBaseOregonDesignSamplingBrainCohortMild Cognitive ImpairmentBiological MarkersFundingCerebrospinal FluidResearch PersonnelPharmaceutical PreparationsClinical ResearchAmyloid Beta-ProteinMissionResponsePre-ClinicalInnovationNeuroimaging
Grant awards (59)
Biomarker-Core$158,187
P30 · FY2025 · AG · contact PI
Biomarker Core$92,172
P30 · FY2024 · AG · contact PI
Biomarker Core$92,174
P30 · FY2023 · AG · contact PI
Therapeutic targeting a membrane estrogen receptor with a novel non-steroidal compound for Alzheimer's disease$766,929
R56 · FY2022 · AG
Biomarker Core$97,337
P30 · FY2022 · AG · contact PI
Biomarker Core$92,174
P30 · FY2021 · AG · contact PI
A novel estrogen modulator for the treatment of Alzheimer's disease$0
I01 · FY2021 · VA · contact PI
Biomarker Core$93,689
P30 · FY2020 · AG · contact PI
A novel estrogen modulator for the treatment of Alzheimer's disease$0
I01 · FY2020 · VA · contact PI
Biological signatures of the cognitive effects of Centella asiatica$301,951
R61 · FY2019 · AT
Biomarkers Core$93,456
P30 · FY2019 · AG · contact PI
ShEEP Request for Seahorse Analyzer for Measuring Mitochondrial Respiration$0
IS1 · FY2019 · VA · contact PI
A novel estrogen modulator for the treatment of Alzheimer's disease$0
I01 · FY2019 · VA · contact PI
Biological signatures of the cognitive effects of Centella asiatica$146,583
R61 · FY2018 · AT
Biomarkers Core$73,806
P30 · FY2018 · AG · contact PI
A novel estrogen modulator for the treatment of Alzheimer's disease$0
I01 · FY2018 · VA · contact PI
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$230,291
U10 · FY2017 · NS · contact PI
Biomarkers Core$84,361
P30 · FY2017 · AG · contact PI
Biological signatures of the cognitive effects of Centella asiatica$73,000
R61 · FY2017 · AT
Targeting tau pathology with copper-modulating strategies in Alzheimers disease$0
I01 · FY2017 · VA · contact PI
Clinical Utility of MicroRNAs as Diagnostic Biomarkers of Alzheimer's Disease$525,094
UH3 · FY2016 · TR
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$224,055
U10 · FY2016 · NS · contact PI
Biomarkers Core$84,361
P30 · FY2016 · AG · contact PI
Optimization and Normalization Studies for Individual CSF Samples$72,967
UH3 · FY2016 · TR
Targeting tau pathology with copper-modulating strategies in Alzheimers disease$0
I01 · FY2016 · VA · contact PI
Clinical Core$626,553
P50 · FY2015 · NS · contact PI
Clinical Utility of MicroRNAs as Diagnostic Biomarkers of Alzheimer's Disease$525,094
UH3 · FY2015 · TR
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$148,003
U10 · FY2015 · NS · contact PI
Characterization of Extracellular Vesicles in Human CSF as Biomarkers for Disease$99,250
UH3 · FY2015 · TR
Biomarkers Core$84,360
P30 · FY2015 · AG · contact PI
Targeting tau pathology with copper-modulating strategies in Alzheimers disease$0
I01 · FY2015 · VA · contact PI
CLINICAL CORE$750,576
P50 · FY2014 · NS · contact PI
Clinical Utility of MicroRNAs as Diagnostic Biomarkers of Alzheimer's Disease$319,860
UH2 · FY2014 · TR
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$215,496
U10 · FY2014 · NS · contact PI
BIOMARKERS AND GENETICS CORE$215,206
P30 · FY2014 · AG · contact PI
Optimization and Normalization Studies for CSF as a Biomarker$77,000
UH2 · FY2014 · TR
Targeting tau pathology with copper-modulating strategies in Alzheimers disease$0
I01 · FY2014 · VA · contact PI
Clinical Utility of MicroRNAs as Diagnostic Biomarkers of Alzheimer's Disease$396,259
UH2 · FY2013 · TR
BIOMARKERS AND GENETICS CORE$213,466
P30 · FY2013 · AG · contact PI
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$211,351
U10 · FY2013 · NS · contact PI
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$264,000
U10 · FY2012 · NS · contact PI
BIOMARKERS AND GENETICS CORE$206,721
P30 · FY2012 · AG · contact PI
BIOMARKERS AND GENETICS CORE$22,989
P30 · FY2012 · AG · contact PI
Comprehensive Oregon Neuroscience Network for Excellence in Clinical Trials$264,000
U10 · FY2011 · NS · contact PI
BIOMARKERS AND GENETICS CORE$208,154
P30 · FY2011 · AG · contact PI
Removing copper for pennies: an affordable strategy for Alzheimer's$0
I01 · FY2011 · VA · contact PI
Removing copper for pennies: an affordable strategy for Alzheimer's$0
I01 · FY2011 · VA · contact PI
EFFECTS OF DOCOSAHEXAENOIC ACID (DHA) IN SLOWING THE PROGRESSION OF AD (DHA)$633,478
U01 · FY2010 · AG · contact PI
BIOMARKERS AND GENETICS CORE$210,832
P30 · FY2010 · AG · contact PI
EFFECTS OF DOCOSAHEXAENOIC ACID (DHA) IN SLOWING THE PROGRESSION OF AD (DHA)$1,209,491
U01 · FY2009 · AG · contact PI
Removing copper for pennies: an affordable strategy for Alzheimer's$0
I01 · FY2009 · VA · contact PI
EFFECTS OF DOCOSAHEXAENOIC ACID (DHA) IN SLOWING THE PROGRESSION OF AD (DHA)$1,647,782
U01 · FY2008 · AG · contact PI
EFFECTS OF DOCOSAHEXAENOIC ACID (DHA) IN SLOWING THE PROGRESSION OF AD (DHA)$1,455,328
U01 · FY2007 · AG · contact PI
Copper Complexing with Tetrathiomolybdate in a Murine Model of Alzheimers Disease$134,798
R21 · FY2007 · AG · contact PI
EFFECTS OF DOCOSAHEXAENOIC ACID (DHA) IN SLOWING THE PROGRESSION OF AD (DHA)$1,173,236
U01 · FY2006 · AG · contact PI
Copper Complexing with Tetrahiomolybdate in a Murine Model of Alzheimers Disease$167,348
R21 · FY2006 · AG · contact PI
A COMPARISON ACROSS AGE GROUPS, GENOTYPE, AND COGNITIVE STATUS$8,706
M01 · FY2005 · RR
Plasma Reliability and Saliva Validity$10,389
M01 · FY2004 · RR
A comparison across age groups, genotype, and cognitive status$9,167
M01 · FY2004 · RR